For instance, EGFR inhibitors, such as gefitinib, erlotinib, or afatinib, can effectively shrink tumors for several months; these drugs eventually stop working for most patients, usually because the cancer cells within the tumor develop additional mutation(s) in the EGFR gene. Here, EGFR is linked to cancer.